United Therapeutics (UTHR) EBT (2009 - 2026)

United Therapeutics has disclosed EBT across 18 years of filings, most recently posting $372.7 million for Q2 2026.

• In Q2 2026, EBT fell 8.74% year-over-year to $372.7 million; the TTM figure through Jun 2026 stood at $1.6 billion (down 2.72% YoY), while the FY2025 annual figure was $1.7 billion, up 11.36% from the prior year.
• EBT came in at $372.7 million for Q2 2026 at United Therapeutics, up from $318.3 million in the prior quarter.
• In the past five years, EBT ranged from a high of $444.0 million in Q4 2025 to a low of $150.6 million in Q2 2022.
• Average EBT over 5 years is $342.7 million, with a median of $353.6 million recorded in 2023.
• The largest YoY upside for EBT was 849.85% in 2022 against a maximum downside of 30.44% in 2022.
• Over 5 years, EBT stood at $178.8 million in 2022, then jumped by 65.21% to $295.4 million in 2023, then jumped by 34.22% to $396.5 million in 2024, then increased by 11.98% to $444.0 million in 2025, then fell by 16.06% to $372.7 million in 2026.
• Per Business Quant data, the three most recent EBT figures were $372.7 million in Q2 2026, $318.3 million in Q1 2026, and $444.0 million in Q4 2025.